DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 01:10:17 01/06/2024 am IST | ||
| 37.6 EUR | +1.21% |
|
| 1 month | -6.61% | ||
| 3 months | -6.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 37.6 | +1.21% |
| 30/24/30 | 37.15 | -0.48% |
| 29/24/29 | 37.33 | +0.46% |
| 28/24/28 | 37.16 | -2.62% |
| 27/24/27 | 38.16 | +0.87% |
Delayed Quote Deutsche Boerse AG
Last update May 01, 2024 at 01:10 am IST
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PE2NCW |
| ISIN | DE000PE2NCW5 |
| Date issued | 21/09/2022 |
| Maturity | 21/06/2024 (19 Days) |
| Parity | 1 : 1 |
| Emission price | 39.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 41.63 € |
|---|---|
| Lowest since issue | 36.83 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat
